October 30, 2024 02:10 PM EDT
Pharma

Ab­b­Vie’s im­munol­o­gy block­busters make up for Hu­mi­ra sales drop in Q3

Katherine Lewin

News Reporter

Ab­b­Vie is lift­ing its prof­it out­look and full-year 2024 guid­ance as its im­munol­o­gy block­busters Skyrizi and Rin­voq beat quar­ter­ly rev­enue es­ti­mates, ac­cord­ing to the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Vi­a­tris' In­dia-based man­u­fac­tur­ing site blocked from ship­ping 11 gener­ic drugs to US

A service from the Financial Times